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(ELIOT). Both APBI and IORT patients have been followed 
prospectively with the same QoL questionnaires: 1 week, 3 
months, 6 months and yearly after breast conserving 
treatment.  
Results: In November 2014 the IORT part of the study 
accrued 192 patients; the APBI part 86 patients. The overall 
response for the QoL questionnaires was 82–98% at the 
different time points. 
There is a non-significant (ns) difference in pain score (VAS 1-
10) 1 week after surgery in favor of APBI patients. After 
completion of radiotherapy this difference is significant in 
favor of the APBI patients, maybe due to wound healing in 
the 4 to 5 weeks after breast conserving surgery. In time this 
difference changes, resulting in a significant difference in 
favor of IORT at 3 and 6 months. 
For fatigue (EORTC C30) the results are comparable; more 
patients are tired (ns) just after surgery for IORT, but again 
less tired at 6 and 12 months. In the explorative analysis, so 
far, co morbidity, not age, seems to influence fatigue. 
Correcting for co morbidity fatigue at 6 and 12 months is 
significant better for IORT. 
 
Mean QoL  
score 
1 week  
after surg 
IORT/APBI 
After RT 
APBI 
3 month 
IORT/APBI 
6 month 
IORT/APBI 
1 year 
IORT/APBI 
IORT pain 2.8   1.9 * 1.8 *  1.7 
APBI pain 2.5  2.2 * 2.6 2.5 2.2 
IORT fatigue 35  25 23** 21** 
APBI fatigue 28 30 26 26  26  
* significant less pain (VAS 1-10);  
** significant less fatigue, when corrected for age and comorbidity (EORTC C30) 
 
Conclusions: This preliminary analysis shows a significant 
better result for pain and fatigue for IORT compared to 
external beam APBI in the first year of follow up. An update 
of the results will be presented including the analysis of the 
confounding factors. 
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Purpose/Objective: To evaluate retrospectively survival and 
local control rates (LCR) of triple negative breast cancer 
(TNBC) subtypes classified in five marker negative (5-NP) and 
core basal (CB) after breast conserving surgery (BCS) and 
intraoperative radiotherapy with electrons (IOERT). 
Materials and Methods: 71 TNBC patients were enrolled. All 
patients were treated with BCS, axillary lymph node 
dissection and received IOERT with a median dose maximum 
of 9.6 Gy as anticipated tumorbed boost, which was followed 
by whole breast irradiation (WBI) to median total doses of 54 
Gy (range 51-57.6) in normofractionation (1.6 - 1.85 Gy 
(5Fx/week). Chemotherapy was applied neoadjuvant (12%), 
adjuvant (75%) or in combination (7%). 
Results: After a median follow-up of 97 months (range 4-170) 
5 ipsilateral breast tumor recurrences (IBTR) were detected 
(7.0%). 8-year actuarial rates of all TNBC patients for local 
control (LCR), metastases free survival (FFM), disease 
specific survival (DSS), and overall survival (OS) amount 91%, 
75%, 80%, and 69%, respectively. Subgroupanalyses revealed a 
trend of inferior outcome for CB in DSS if compared to 5-NP 
(5-NP:83% vs CB:54% for G1/G2, p=0.27, 5-NP:90% vs CB: 79% 
for G3 tumors, p=0.30 and 5-NP G3: 90% vs CB G1/2: 54%, 
p=0.03), whereas LCR seemed to be negative influenced by 
tumor grading G3 (G1/2 (CB and 5-NP):100% vs G3: 88% (5-
NP) and 90% (CB), p=0.65 and 0.82), both without statistical 
significance. 
Conclusions: IOERT as boost modality during BCT of TNBC, 
provides acceptable LCR. CB-subtype and tumorgrading G3 
are negative predictors for survival and LCR, respectively.  
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Purpose/Objective: The aim of the study was to report 
effectiveness, quality of life, toxicity, cosmetic outcomes 
and physical parametres of intraoperative radiotherapy 
(IORT) given as a boost during breast conserving surgery (BCS) 
followed by adjuvant whole breast radiotherapy (WBI).  
Materials and Methods: Between 2008 and 2011 in 150 breast 
cancers patients treated in our centre intraoperative 
radiotherapy as a tumor bed boost was applied using mobile 
electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). 
IORT boost (10 Gy) was followed by 50 Gy whole-breast 
external beam radiotherapy (EBRT). Chemotherapy, if 
indicated, was given before EBRT. The observation period 
was 1,5-5,5 years. 
Clinical outcomes was assessed by physical examination, 
photos of the breast with Harris-Limbergen scale, EORTC 
questionnaires (QLQ-C30 and QLQ-BR23), analysis of acute 
and late toxicity (CTCAE v 3.0 and LENT-SOMA scales), 
mammography, ultrasounds and chest X-ray. 
Results: There was no local recurrences. Acute skin reactions 
in grade 1 and 2 were observed in 31% of pts in 1 month post 
RT and 9% in 6 months post RT, with no acute and late 
toxicities in grade 3 and 4. 
The cosmetic outcome was good to excellent in 81,5% of pts 
1 month post RT and 87% 3 years post RT. 
Pain in breast was observed in 53 % pts 1 month post RT and 
21% 6 months posr RT, hyperesthesia of the skin in 17,0 % pts. 
The data was tested with Mantel-Haenschel test. There was 
no statistical significance.  
The late toxicity was evaluated one year after radiation 
therapy. The edema of breast was reported by 18 % of pts.  
The telangiectasia of breast skin has occurred in 25 % of pts. 
Retraction of the breast occurred in 39% of pts. Fibrosis was 
detected in 60% of patients. 
There was no statistical significance change in quality of life 
in any follow-up period based on Friedman test analysis 
(p=0,2143). 
Patients were treated using all available electron beam 
energies: 6 MeV energy was used in 58% cases but also 9 MeV, 
